HistoSonics developed novel sonic beam therapy for the destruction of targeted liver tissue.
The new targeted liver therapy helps in providing timely access to non-invasive liver treatment and destructs targeted liver tissue.
This is the first automated external beam therapy which makes use of acoustic energy and helps clinicians in mechanically destroy tissues in the liver without the use of incisions, ionizing radiation or heat.
The ongoing results suggest that the complete non-invasive treatment used for the destruction of targeted liver tissue provides many advantages for patients, which does not exist in today’s world.
Some of its advantages include providing equal treatment effect during the entire treatment volume in precise and predictable treatment zones. Results from early and pre-clinical suggested that histotripsy mainly preserves critical structures such as the liver capsule, large vessels and ducts present within or adjacent to the treated volume of tissue. Moreover, it also enables physicians to monitor destruction of tissue under continuous real time visualization.
U.S. Food and Drug Administration (FDA) has granted the company Breakthrough Device Designation for novel sonic beam therapy.
